These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20223183)

  • 1. [Progress in hypertension and diabetes mellitus].
    Cordero A; Fácila L; Galve E; Mazón P
    Rev Esp Cardiol; 2010 Jan; 63 Suppl 1():101-15. PubMed ID: 20223183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances in arterial hypertension and diabetes mellitus].
    Cordero A; Lekuona I; Galve E; Mazón P;
    Rev Esp Cardiol (Engl Ed); 2012 Jan; 65 Suppl 1():12-23. PubMed ID: 22269836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progress in hypertension and diabetes in 2010].
    Cordero A; Fácila L; Alonso A; Mazón P
    Rev Esp Cardiol; 2011; 64 Suppl 1():20-9. PubMed ID: 21276487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognosis of diabetic patients with ischemic cardiopathy].
    Zamora A; Marrugat J
    Rev Esp Cardiol; 2002 Jul; 55(7):751-62. PubMed ID: 12113703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
    Sanoski CA
    Pharmacotherapy; 2009 Feb; 29(2):193-212. PubMed ID: 19170589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence, awareness, treatment and control of hypertension in a Canarian population. Relationship with glucose tolerance categories. The Guía Study.
    de Pablos-Velasco P; Martínez-Martín FJ; Rodríguez Pérez F; Urioste LM; García Robles R
    J Hypertens; 2002 Oct; 20(10):1965-71. PubMed ID: 12359974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment guidelines for a patient with diabetes and hypertension.
    Mogensen CE
    J Hypertens Suppl; 2003 Mar; 21(1):S25-30. PubMed ID: 12769164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of patients with ischemic heart disease and diabetes].
    Zaliūnas R; Babarskiene MR; Brazdzionyte J
    Medicina (Kaunas); 2004; 40(2):192-7. PubMed ID: 15007279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [beta-blockers in the treatment of hypertension in diabetic patients].
    Kobusiak-Prokopowicz M
    Pol Merkur Lekarski; 2004 Apr; 16(94):389-93. PubMed ID: 15517941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control.
    Perkins JM; Davis SN
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):147-52. PubMed ID: 18316950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.
    Düsing R; Sellers F
    Curr Med Res Opin; 2009 Sep; 25(9):2287-301. PubMed ID: 19635044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing cardiovascular and renal risk: the potential of direct renin inhibition.
    Sever PS; Gradman AH; Azizi M
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):65-76. PubMed ID: 19502253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
    Zimmermann M; Unger T
    Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients with hypertension and diabetes mellitus: advances in the evidence for intensive treatment.
    White WB; Prisant LM; Wright JT
    Am J Med; 2000 Feb; 108(3):238-45. PubMed ID: 10723978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.